image
Healthcare - Medical - Devices - NASDAQ - US
$ 2.59
-2.26 %
$ 2.37 M
Market Cap
-0.31
P/E
1. INTRINSIC VALUE

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.[ Read More ]

The intrinsic value of one HSCS stock under the base case scenario is HIDDEN Compared to the current market price of 2.59 USD, Heart Test Laboratories, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart HSCS

image
FINANCIALS
18.6 K REVENUE
261.17%
-6.31 M OPERATING INCOME
-3.15%
-6.61 M NET INCOME
-3.95%
-6.07 M OPERATING CASH FLOW
-5.14%
-125 K INVESTING CASH FLOW
-584.24%
10.3 M FINANCING CASH FLOW
58.29%
0 REVENUE
0.00%
-2.08 M OPERATING INCOME
-10.42%
-2.05 M NET INCOME
-11.13%
-2.02 M OPERATING CASH FLOW
-31.39%
-833 INVESTING CASH FLOW
99.24%
552 K FINANCING CASH FLOW
46.28%
Balance Sheet Decomposition Heart Test Laboratories, Inc.
image
Current Assets 7.35 M
Cash & Short-Term Investments 5.81 M
Receivables 0
Other Current Assets 1.55 M
Non-Current Assets 2.15 M
Long-Term Investments 0
PP&E 560 K
Other Non-Current Assets 1.59 M
Current Liabilities 1.75 M
Accounts Payable 448 K
Short-Term Debt 602 K
Other Current Liabilities 701 K
Non-Current Liabilities 434 K
Long-Term Debt 434 K
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall Heart Test Laboratories, Inc.
image
Revenue 18.6 K
Cost Of Revenue 6.08 K
Gross Profit 12.5 K
Operating Expenses 6.32 M
Operating Income -6.31 M
Other Expenses 299 K
Net Income -6.61 M
RATIOS
67.31% GROSS MARGIN
67.31%
-33901.99% OPERATING MARGIN
-33901.99%
-35511.87% NET MARGIN
-35511.87%
-90.27% ROE
-90.27%
-69.51% ROA
-69.51%
-80.66% ROIC
-80.66%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Heart Test Laboratories, Inc.
image
Net Income -6.61 M
Depreciation & Amortization 95.1 K
Capital Expenditures -125 K
Stock-Based Compensation 405 K
Change in Working Capital -504 K
Others 171 K
Free Cash Flow -6.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Heart Test Laboratories, Inc.
image
HSCS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Heart Test Laboratories, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement Southlake, TX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has included AI-ECG technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule under assignment APC 5734. This approval would allow outpatient settings to receive reimbursement for HeartSciences' MyoVista® wavECGTM algorithm and MyoVista® InsightsTM low ejection fraction algorithm, upon FDA clearance. The payment rate is expected to be $125. globenewswire.com - 3 days ago
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit Southlake, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.  d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that Company CEO Andrew Simpson has been invited to participate in the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC and hosted by M-Vest, from Tuesday October 15 to Thursday October 17, 2024. globenewswire.com - 1 month ago
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the first quarter fiscal 2025 ended July 31, 2024 and provided a business update. globenewswire.com - 2 months ago
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the close of a non-dilutive financing, with $1.9 million in net proceeds.  The unsecured loan note has an 18-month maturity date and follows the recent 12-month extension of a $500,000 loan note to September 2025. globenewswire.com - 2 months ago
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results Southlake, TX, July 29, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the fiscal year 2024 ended April 30, 2024 and provided a business update. globenewswire.com - 3 months ago
Innovation Value Institute Analysis Demonstrates HeartSciences' MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency Southlake, TX, July 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced an analysis published by the Innovation Value Institute (IVI) titled “Introduction of AI assisted Digital Health Technology to Improve Cardiovascular Pathway Efficiency” focused on the MyoVista® wavECG™'s potential to radically improve the cardiovascular pathway efficiency. globenewswire.com - 3 months ago
HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare Southlake, TX, July 25, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the MyoVista® wavECGTM has been selected by the Innovation Value Institute as a technology which can drive the radical transformation of healthcare and has been invited to demonstrate and discuss the MyoVista wavECG at the 4th Digital Health Symposium at the United Nations General Assembly to be held in New York, USA in September 2024. globenewswire.com - 3 months ago
HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction Southlake, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that intellectual property (IP) exclusively licensed to HeartSciences has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for the detection of left ventricular (LV) and/or right ventricular (RV) dysfunction using deep learning, further strengthening the Company's AI-ECG IP portfolio. Heart failure (HF) is a growing worldwide public health issue affecting 64 million people annually1 and is associated with high mortality, lower quality of life and reduced physical capacity while placing substantial costs on the healthcare system. globenewswire.com - 4 months ago
HeartSciences Regains Compliance with Nasdaq Listing Requirements Southlake, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that on June 3, 2024, the Company received formal notice from the Listing Qualifications Staff of the Nasdaq Stock Market LLC indicating that HeartSciences has regained compliance with bid price requirement as set forth in Listing Rule 5550(a)(2), and that the Company is therefore in compliance with the Nasdaq Capital Market's listing requirements and the scheduled hearing has now been cancelled. globenewswire.com - 5 months ago
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio Southlake, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has been granted Indian Patent Application 201817014481 by the Indian Patent Office (IPO). To date, HeartSciences has been granted nine US patents and 35 international patents for a total of 44 granted patents. globenewswire.com - 5 months ago
HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG Patent covers use of AI-ECG for any echo measure of diastolic function, which is crucial for heart screening and early detection of heart disease Patent covers use of AI-ECG for any echo measure of diastolic function, which is crucial for heart screening and early detection of heart disease globenewswire.com - 6 months ago
HeartSciences to Present at the LD Micro Invitational XIV Conference Southlake, TX, April 02, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences  (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson is scheduled to present at the LD Micro Invitational XIV Conference on Tuesday April 9, 2024 at 5:00pm ET at the Sofitel New York. Mr. Simpson will also be hosting one-on-one meetings through the conference. globenewswire.com - 7 months ago
8. Profile Summary

Heart Test Laboratories, Inc. HSCS

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 2.37 M
Dividend Yield 0.00%
Description Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
Contact 550 Reserve Street, Southlake, TX, 76092-1552 https://heartsciences.com
IPO Date June 16, 2022
Employees 15
Officers Mr. Andrew Simpson Chief Executive Officer, President & Chairman of the Board of Directors Mr. Mark T. Hilz Chief Operating Officer, Secretary & Director Ms. Danielle Watson Chief Financial Officer & Treasurer